PlainMeds provides educational information only. This is not medical advice. Always consult your doctor or pharmacist.

Drug side effects

atorvastatin Side Effects

The reactions most often reported to the FDA for atorvastatin (also sold as Lipitor), with demographics, serious outcomes, and reporting trends.

Data updated 2026-05-15

240,204
FAERS reports

Data from the FDA Adverse Event Reporting System (FAERS), 2000 to 2025. A FAERS report records a temporal association, not proof of cause. See our methodology for how figures are compiled and de-duplicated.

The most commonly reported side effects of atorvastatin come from 240,204 reports to the FDA, broken down here by frequency, patient demographics, and serious outcomes.

This page analyzes 240,204 reports to the FDA Adverse Event Reporting System (FAERS) for atorvastatin (Lipitor): the reactions reported most often, who reported them, serious outcomes such as hospitalization, and year-over-year trends. A FAERS report does not prove the drug caused the effect, and report volume tracks how widely a drug is used, not how likely an effect is for any one person. Educational information, not medical advice.

Total Reports

240,204

Reports Mentioning Death

18,385

7.7% of reports — not proof the medicine caused the death

Hospitalizations

68,513

28.5% of reports

Top Indication

Product Used For Unknown Indication

Most Reported Adverse Reactions

FATIGUE
13,812
NAUSEA
12,425
TYPE 2 DIABETES MELLITUS
11,244
DIARRHOEA
11,037
DYSPNOEA
11,029
PAIN
10,041
MYALGIA
9,801
DIZZINESS
9,713
HEADACHE
9,650
ASTHENIA
8,837
ARTHRALGIA
8,510
PAIN IN EXTREMITY
8,172
FALL
7,836
DEATH
7,428
MALAISE
6,892
WEIGHT DECREASED
6,768
MYOCARDIAL INFARCTION
6,663
VOMITING
6,318

Who Reports Side Effects

Gender Distribution

Female 121,275 (54%)
Male 102,566 (45%)
Unknown 2,298

Age Distribution

0-17 569 (0%)
18-44 7,262 (5%)
45-64 56,931 (39%)
65-74 44,581 (30%)
75+ 38,431 (26%)

Reporting Trend by Year

2000 2025

Reactions in Death Reports

Top reactions reported in 18,385 reports where death was an outcome. These are voluntarily reported and do not establish causation.

Reaction Reports
DEATH 7,408
MYOCARDIAL INFARCTION 1,271
PNEUMONIA 1,099
RENAL FAILURE 1,015
DYSPNOEA 1,012
SEPSIS 792
DIARRHOEA 788
ASTHENIA 763
CARDIAC ARREST 763
FALL 762
NAUSEA 722
FATIGUE 717
RESPIRATORY FAILURE 672
CARDIAC FAILURE CONGESTIVE 660
CEREBROVASCULAR ACCIDENT 597
ACUTE KIDNEY INJURY 586
VOMITING 565
HYPOTENSION 561
PAIN 555
CARDIO-RESPIRATORY ARREST 553

Reactions in Hospitalization Reports

Top reactions in 68,513 reports where hospitalization was an outcome.

Reaction Reports
DYSPNOEA 5,530
PNEUMONIA 4,694
FALL 4,618
NAUSEA 4,471
MYOCARDIAL INFARCTION 4,368
FATIGUE 4,074
DIARRHOEA 3,997
ASTHENIA 3,897
PAIN 3,470
CEREBROVASCULAR ACCIDENT 3,390
DIZZINESS 3,265
VOMITING 3,128
CHEST PAIN 2,995
HEADACHE 2,987
PYREXIA 2,875
WEIGHT DECREASED 2,865
MALAISE 2,785
ANAEMIA 2,588
CARDIAC FAILURE CONGESTIVE 2,585
HYPOTENSION 2,430

Compare atorvastatin vs alirocumab →

What the FAERS Data Reveals About atorvastatin Side Effects

The FDA Adverse Event Reporting System (FAERS) contains 240,204 voluntary reports linked to atorvastatin and its brand equivalents (Lipitor), spanning 2000 through 2025. Of those, 18,385 (7.7%) listed death as an outcome and 68,513 (28.5%) involved hospitalization. The most common indication reported alongside adverse events was Product Used For Unknown Indication.

Demographic breakdowns help contextualize who is being exposed to the drug. Of reports with known sex, 54% were female and 45% male; age distribution skews toward 45-64, with 56,931 reports in that bracket. The single most reported reaction is fatigue with 13,812 submissions, followed by nausea and type 2 diabetes mellitus.

How to read these numbers

FAERS is a signal-detection tool, not a scorecard. Reports are voluntary, and a single case may list multiple suspect drugs, so numbers above should not be read as incidence rates or per-patient risk. Widely prescribed drugs naturally accumulate more reports than niche therapies even when individual risk is low. These aggregates are useful for spotting patterns that merit further pharmacovigilance, not for choosing between medications. This page is for educational reference only and is not medical advice, speak with a licensed clinician about any side-effect concerns.